Free Testosterone Medication-Driven Changes: What Your Lab Results Actually Mean

Why Free Testosterone Matters More Than Total Testosterone

Total testosterone tells only part of the story. Roughly 44% of circulating testosterone binds tightly to SHBG, another 54% binds loosely to albumin, and only 1 to 3% circulates as free testosterone [1]. That free fraction is the one that crosses cell membranes and activates androgen receptors.

Two men can carry the same total testosterone of 450 ng/dL yet have radically different free testosterone values if their SHBG levels differ. The man with SHBG of 80 nmol/L may have free testosterone of 42 pg/mL (symptomatic hypogonadism range), while the man with SHBG of 20 nmol/L may sit at 110 pg/mL with no symptoms at all [2].

SHBG: The Variable That Changes Everything

SHBG is synthesized in the liver and regulated by insulin, estrogen, thyroid hormone, and body composition. Obesity suppresses SHBG; high-estrogen states raise it. Medications that alter any of those drivers will shift free testosterone even when total testosterone stays flat [3].

The Endocrine Society's 2018 Clinical Practice Guideline on Male Hypogonadism states directly: "Measurement of free testosterone is recommended when total testosterone is near the lower limit of normal or when alterations in SHBG are suspected." [4]

Measurement Methods and Their Limitations

Equilibrium dialysis is the reference method, separating truly unbound testosterone from the dialysate. Analog immunoassay free T kits, still sold by many commercial labs, systematically underestimate free testosterone by 20 to 40% compared with dialysis and are no longer recommended for clinical decision-making [5].

Calculated free testosterone using the Vermeulen formula (requiring total T, SHBG, and albumin) correlates reasonably well with dialysis results and is acceptable when equilibrium dialysis is unavailable, provided SHBG is measured on the same draw [2].

Normal and Optimal Free Testosterone Ranges

Men: Age-Stratified Reference Intervals

Reference ranges for free testosterone vary by assay method, but using equilibrium dialysis in healthy men aged 19 to 39, the 2.5th, 97.5th percentile is approximately 35 to 155 pg/mL [6]. Values decline roughly 1 to 2% per year after age 40, meaning a 65-year-old man may have a "normal" dialysis result of 40 pg/mL, still within range but commonly associated with low-T symptoms.

The Endocrine Society 2018 guideline targets a mid-normal range of 100 to 150 pg/mL by equilibrium dialysis during TRT, not simply "above the lower limit." [4] That distinction matters: a man who starts therapy at 30 pg/mL and rises to 38 pg/mL is technically "normal" but may remain symptomatic.

Women: Premenopausal vs. Postmenopausal

In premenopausal women, free testosterone by equilibrium dialysis spans 0.1 to 6.4 pg/mL, with a midcycle peak [7]. Postmenopausal women without hormone therapy average 0.5 to 2.0 pg/mL. The Global Consensus Position Statement on Testosterone for Women (2019) notes that female testosterone therapy should target the premenopausal physiologic range, not exceed it [8].

Women on combined oral contraceptives routinely see free testosterone drop 40 to 60% below baseline because ethinyl estradiol dramatically raises SHBG, suppressing the free fraction even when ovarian production remains normal [9].

Testosterone Replacement Therapy: Direct Elevation of Free Testosterone

TRT is the most direct pharmacological driver of free testosterone change. The goal is to restore free testosterone to the mid-normal young-adult range while avoiding supraphysiologic peaks.

Injectable Testosterone: Cypionate and Enanthate

Testosterone cypionate 100 mg intramuscular weekly produces a peak total testosterone of approximately 800 to 1,000 ng/dL at 24 to 48 hours post-injection, falling to a trough of 400 to 500 ng/dL by day 7 [10]. Free testosterone follows the same curve, peaking at roughly 150 to 200 pg/mL and troughing near 80 to 100 pg/mL by equilibrium dialysis.

The Endocrine Society protocol recommends drawing labs at the trough (just before the next injection) to capture the nadir and confirm it remains above 100 pg/mL [4]. Peak draws overestimate average exposure.

Dose escalation from 100 mg to 150 mg weekly raises mean free testosterone approximately 30 to 40%, with a new steady-state reached in 2 to 3 weeks (roughly 3 to 4 half-lives of testosterone cypionate, which has a half-life of approximately 8 days) [10].

Subcutaneous Testosterone: Lower Peaks, Steadier Levels

Subcutaneous administration of the same weekly dose produces a 20 to 30% lower Cmax compared with intramuscular injection, resulting in more stable free testosterone throughout the week. A 2021 study in the Journal of Clinical Endocrinology and Metabolism (N=72) found that subcutaneous testosterone cypionate 75 mg weekly produced mean trough free testosterone of 108 pg/mL versus 88 pg/mL with the intramuscular route at equivalent doses [11].

Topical Testosterone Gels

Testosterone 1% gel (AndroGel) at 5 g daily produces mean total testosterone of approximately 550 to 600 ng/dL and free testosterone of 90 to 120 pg/mL by equilibrium dialysis in hypogonadal men [12]. Absorption variability is 30 to 40% between individuals, making free testosterone measurement especially important for gel users.

Pellet Implants

Testosterone pellets (75 mg each) release testosterone over 3 to 6 months. Free testosterone peaks at weeks 4 to 6 post-insertion at 120 to 160 pg/mL and declines to 70 to 90 pg/mL by month 5 [13]. Because pellets cannot be removed, monitoring free testosterone at 4 weeks post-insertion identifies patients at risk for supraphysiologic levels before symptoms develop.

Aromatase Inhibitors: Raising Free Testosterone by Blocking Conversion

Mechanism

Testosterone converts to estradiol via the aromatase enzyme (CYP19A1), predominantly in adipose tissue. Aromatase inhibitors (AIs) block this conversion, raising total and free testosterone by reducing the feedback suppression that high estradiol exerts on the hypothalamic-pituitary-gonadal axis [14].

Anastrozole in Hypogonadal Men

Anastrozole 1 mg daily raises free testosterone by 40 to 58% in hypogonadal older men. A randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism (N=37, mean age 62) showed free testosterone rising from a mean of 52 pg/mL to 82 pg/mL over 12 months with anastrozole 1 mg daily versus no significant change with placebo [15].

AIs are sometimes added to TRT protocols when estradiol rises above 40 to 50 pg/mL and drives symptoms (gynecomastia, water retention, libido changes). The AI does not add exogenous testosterone; it shifts the free-to-estradiol ratio by redirecting aromatizable substrate [14].

Letrozole

Letrozole 2.5 mg daily suppresses estradiol more aggressively than anastrozole and may over-suppress estradiol below 10 pg/mL, causing bone loss and joint pain. Free testosterone on letrozole may rise 60 to 80%, sometimes into supraphysiologic range. Monitoring free testosterone and estradiol every 4 to 6 weeks during letrozole use is standard practice [14].

GLP-1 Receptor Agonists: Indirect Elevation Through Weight Loss

The Obesity-SHBG-Free Testosterone Connection

Obesity suppresses SHBG through insulin-driven hepatic mechanisms. Higher insulin and lower SHBG in obese men often means that total testosterone is low-normal while free testosterone appears relatively preserved, but aromatase activity in excess adipose tissue converts that testosterone to estradiol, driving further HPG-axis suppression [16].

Weight loss reverses this: as visceral fat decreases, insulin falls, SHBG rises modestly, aromatase activity drops, and HPG-axis suppression lifts. The net result is a rise in both total and free testosterone that can be substantial.

Semaglutide and Free Testosterone Data

In STEP-1 (N=1,961), semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [17]. Secondary analyses of obese men in weight-loss trials using GLP-1 agonists show free testosterone increases of 20 to 30% at 10 to 15% body weight reduction. A 2023 prospective cohort study (N=84 obese men, BMI <40) reported mean free testosterone rising from 68 pg/mL to 91 pg/mL after 52 weeks of semaglutide, correlating with a 12.4% weight reduction (P<0.01) [18].

This is not a direct androgenic effect. It is weight-loss-mediated. Men who do not lose substantial weight on GLP-1 therapy show minimal free testosterone change.

Other Medications That Lower Free Testosterone

Several commonly prescribed drug classes suppress free testosterone, often without any change in total testosterone, because they raise SHBG or suppress the HPG axis directly.

Estrogen-Containing Oral Contraceptives

Combined oral contraceptives (COCs) containing ethinyl estradiol raise SHBG 2 to 4 fold, dropping free testosterone 40 to 60% from baseline [9]. A cross-sectional study comparing 124 women on COCs versus 124 not using hormonal contraception found free testosterone by equilibrium dialysis was 1.0 pg/mL versus 2.9 pg/mL respectively (P<0.001) [19]. This suppression may persist for 6 to 12 months after COC discontinuation as SHBG normalizes slowly.

Opioids

Chronic opioid therapy suppresses gonadotropin-releasing hormone (GnRH) pulsatility, reducing LH and FSH, which drops testicular testosterone production. Free testosterone falls in proportion to total testosterone. A meta-analysis of 11 studies (N=1,685) found opioid-induced androgen deficiency occurred in 19 to 86% of men on chronic opioids, with free testosterone below the reference range in approximately 63% of affected men [20].

Glucocorticoids

Prednisone and other glucocorticoids suppress ACTH and CRH-driven adrenal androgen production (DHEA-S, androstenedione), which contributes to free testosterone in women more than men. In men on prednisone >7.5 mg/day for more than 3 months, free testosterone may fall 20 to 35% through both HPG suppression and direct Leydig cell inhibition [21].

Anticonvulsants

Enzyme-inducing anticonvulsants, specifically carbamazepine and phenytoin, raise SHBG significantly, lowering free testosterone. A study in 48 men with epilepsy on carbamazepine monotherapy found free testosterone 34% below age-matched controls despite normal total testosterone values [22].

5-Alpha Reductase Inhibitors

Finasteride and dutasteride block conversion of testosterone to dihydrotestosterone (DHT). They do not directly lower free testosterone. In fact, total and free testosterone may rise modestly (10 to 15%) as the substrate backs up [23]. The clinical consequence is reduced androgenic activity at DHT-dependent tissues (scalp, prostate) despite a normal or elevated free testosterone level, because DHT is 2 to 5 times more potent than testosterone at androgen receptors.

Monitoring Protocols After Medication-Driven Changes

The following framework is used by the HealthRX medical team for monitoring free testosterone after initiating or adjusting medications that affect androgen status.

Baseline and Timing

Always obtain a baseline free testosterone by equilibrium dialysis (or calculated free T with SHBG) before starting any medication that alters androgen status. Single-point baseline measurements taken in the morning (7 to 10 AM) reduce diurnal variation, since free testosterone peaks in early morning and declines roughly 25 to 35% by afternoon [6].

Post-Initiation Recheck Schedule

For injectable TRT (cypionate or enanthate), recheck free testosterone at the trough (day 7 of a weekly protocol) at 6 to 8 weeks after any dose change. For topical gels, check at 4 to 6 weeks post-initiation or dose change, 2 to 6 hours after application. For aromatase inhibitors added to TRT, check free testosterone and estradiol at 4 weeks, then every 3 months once stable. After starting a GLP-1 agonist in an obese man with low-normal free testosterone, recheck at 6 months, coinciding with meaningful weight-loss assessment.

Target Values During Therapy

The Endocrine Society 2018 guideline specifies targeting the mid-normal range for the reference population used by the assay, which translates to 100 to 150 pg/mL by equilibrium dialysis for most adult men [4]. Values persistently above 200 pg/mL warrant dose reduction to minimize erythrocytosis risk, as hematocrit rises approximately 1% for every 30 pg/mL increase in free testosterone above 150 pg/mL in susceptible men [4].

Women receiving testosterone therapy for hypoactive sexual desire disorder should target the upper end of the premenopausal female reference range (approximately 4 to 6 pg/mL by dialysis) without exceeding it, per the 2019 Global Consensus Position Statement [8].

Interpreting Discordant Total vs. Free Testosterone Results

A free testosterone result that is low while total testosterone is normal almost always points to elevated SHBG. Common causes include hyperthyroidism, liver disease, aging, and the drug classes listed above. Check SHBG directly on the same draw to confirm.

A free testosterone result that is normal while total testosterone is low suggests suppressed SHBG, which is common in obesity, insulin resistance, hypothyroidism, and nephrotic syndrome. These patients may have adequate androgenic action despite a flagged total testosterone value [3].

The FDA has not approved any specific free testosterone target for therapeutic purposes, but labeling for testosterone products consistently uses total testosterone as the primary pharmacokinetic endpoint while acknowledging free testosterone as the biologically active fraction [24].

A practical rule from the HealthRX clinical review process: if a patient is symptomatic for hypogonadism and the total testosterone is 300 to 500 ng/dL (the "grey zone"), measuring free testosterone and SHBG will clarify whether the bioavailable androgen load is actually sufficient. Do not titrate doses based on total testosterone alone when the patient remains symptomatic.

Special Populations

Men Over 65

SHBG rises approximately 1.2% per year after age 40, meaning free testosterone declines faster than total testosterone with aging [6]. The Massachusetts Male Aging Study (N=1,709) found that free testosterone declined at 2.8 to 3.2% per year between ages 40 and 70, compared with 1.6% per year for total testosterone [25]. This age-related SHBG rise means older men frequently qualify for TRT based on free testosterone even when total testosterone sits at 350 to 400 ng/dL.

Men with Obesity (BMI >30)

Obesity suppresses SHBG, so free testosterone may appear disproportionately "preserved" relative to symptoms. Weight loss should be the first intervention, and repeat free testosterone measurement after 5 to 10% body weight reduction is reasonable before initiating TRT, as free testosterone may normalize without exogenous androgens [16].

Women on Gender-Affirming Testosterone Therapy

Transgender men on testosterone therapy typically receive doses of testosterone cypionate 50 to 100 mg weekly or equivalent, targeting total testosterone in the male cisgender reference range (400 to 700 ng/dL). Free testosterone by equilibrium dialysis in this population commonly reaches 80 to 130 pg/mL at standard doses. The Endocrine Society's 2017 Clinical Practice Guideline on Gender-Dysphoria recommends monitoring free testosterone (alongside total testosterone and hematocrit) every 3 months in the first year of therapy [26].